Marshall Wace, LLP Athenex, Inc. Transaction History

Marshall Wace, LLP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$1.36 - $2.94 $26,593 - $57,488	-19,554 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$2.97 - $4.84 $58,075 - $94,641	19,554 New	19,554 $59,000
Q1 2021 May 17, 2021	SELL	$4.08 - $14.75 $93,852 - $339,294	-23,003 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$11.06 - $14.01 $1.14 Million - $1.44 Million	-102,939 Reduced 81.74%	23,003 $254,000
Q3 2020 Nov 16, 2020	BUY	$10.26 - $14.55 $669,834 - $949,911	65,286 Added 107.63%	125,942 $1.52 Million
Q2 2020 Aug 13, 2020	BUY	$7.11 - $13.76 $431,264 - $834,626	60,656 New	60,656 $834,000
Q2 2018 Aug 14, 2018	SELL	$15.88 - $19.5 $230,260 - $282,750	-14,500 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$13.53 - $17.47 $196,185 - $253,314	14,500 New	14,500 $247,000

1.46M

Ticker ATNX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 156,790,000
Market Cap $1.57M
Description
Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of cancer. It operates through three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The company's Orascovery product candidates include Oral paclitaxel and encequidar,...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.